SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Another_Just_me who wrote (12115)4/17/2019 12:58:01 PM
From: HardToFind  Read Replies (1) | Respond to of 12871
 
You're right. Drug approval is likely to be closer to one year instead of two and a half years.

The FDA has 10 months plus whatever time the company takes to answer the FDA's questions. I presume the questions will be less complex than that for a cancer drug.

And perhaps there's a chance that the FDA prioritizes this drug...but I sort of doubt that will happen. As you say, it's not a cancer drug.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News